AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (February 26, 2008). doi:10.1152/ajpendo.00131.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/5/E898    most recent
00131.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Takahashi, K.
Right arrow Articles by Ishida, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, K.
Right arrow Articles by Ishida, H.
Submitted on February 26, 2007
Accepted on February 12, 2008

JNK- and I{kappa}B-dependent pathways regulate MCP-1, not adiponectin, release from artificially hypertrophied 3T3-L1 adipocytes preloaded with palmitate in vitro

Kazuto Takahashi1, Shinya Yamaguchi1, Tatsuhiro Shimoyama1, Hiroyuki Seki1, Hidenori Katsuta1, Kaoru Miyokawa1, Toshiaki Tanaka1, Katsuhiko Yoshimoto1, Hideki Ohno2, Shinya Nagamatsu3, and Hitoshi Ishida1*

1 Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Tokyo, Japan
2 Molecular Predictive Medicine and Sport Science, Kyorin University School of Medicine, Mitaka, Tokyo, Japan
3 Biochemistry, Kyorin University School of Medicine, Mitaka, Tokyo, Japan

* To whom correspondence should be addressed. E-mail: ishida{at}kyorin-u.ac.jp.

Obese conditions increase the expression of adipocytokine monocyte chemoattractant protein-1 (MCP-1) in adipose tissue, as well as increasing MCP-1 plasma levels. To investigate the mechanism behind increased MCP-1, we used a model in which 3T3-L1 adipocytes were artificially hypertrophied by preloading with palmitate in vitro. As observed in obesity, under our model conditions palmitate preloaded cells showed significantly increased oxidative stress and increased MCP-1 expression. This increased MCP-1 expression was enhanced by adding exogenous tumor necrosis factor-{alpha} (TNF-{alpha}) (17.8-fold vs. control, p<0.01) rather than interleukin-1{beta} (IL-1{beta}) (2.6-fold vs. control, p<0.01). However, endogenous TNF-{alpha} and IL-1{beta} release was not affected in hypertrophied cells, suggesting these endogenous cytokines do not mediated hypertrophy-induced increase in MCP-1. MCP-1 secretion from hypertrophied cells was significantly decreased by treatment with antioxidant N-acetyl-cysteine, JNK inhibitors SP600125 and JIP-1 peptide, and I{kappa}B phosphorylation inhibitors BAY 11-7085 and BMS-345541 (p<0.01). MCP-1 secretion was not affected by PPAR-{gamma} antagonists assayed. Adiponectin, another adipocytokine studied in parallel, also showed increased release in hypertrophied relative to control cells. But in contrast to MCP-1, adiponectin release was significantly suppressed by both exogenous TNF-{alpha} and IL-1{beta}, as well as by PPAR-{gamma} antagonists bisphenol A diglycidyl ether and T0070907 (p<0.01). JNK inhibitors and I{kappa}B phosphorylation inhibitors showed no significant effect on adiponectin. We conclude that adipocyte hypertrophy through palmitate loading causes oxidative stress, which in turn increases MCP-1 expression and secretion through JNK and I{kappa}B signaling. In contrast, the parallel increase in adiponectin expression appears to be related to the PPAR-{gamma} ligand properties of palmitate.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.